Notice of Results

RNS Number : 5859T

Epistem Holdings plc

07 October 2014

 



Notice of Results

7 October 2014

Epistem Holdings Plc (LSE: EHP), the  personalised medicine and biotechnology company will be announcing its preliminary results for the year ended 30 June 2014 on Tuesday, 28 October 2014.

An analysts' meeting will be held at the London Stock Exchange, 10 Paternoster Square, London EC4M 7LS in Avenue 3 at 9.30am.

If you would like to attend, please contact either Anna Dunphy or Mike Wort at Walbrook PR.

Epistem Plc
Matthew Walls	Chief Executive Officer	[phone]
John Rylands	Finance Director	[phone]
Peel Hunt LLP
James Steel		[phone]
Clare Terlouw		[phone]
Walbrook PR
Mike Wort / Anna Dunphy		[phone]

  [e-mail] 

Notes to Editors:

About Epistem

Epistem is a personalised medicine and biotechnology company commercialising its expertise in adult stem cells in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and biomarkers (Genedrive®), target discovery therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Biomarkers), Contract Research Services and Novel Therapies.

 

END

 

 

NORDMMGGVVGGDZM